Visiopharm today announces that it will provide The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) with AI-powered precision pathology solutions. OSUCCC – James will test Visiopharm’s next generation APPs which include automated identification of patient tissue versus control tissue on the slide and automatic queue of analysis, which includes identification of tumor cells versus pre-invasive/stromal cells, quantification of structural content as well as visualization of heterogeneity. This powerful workflow and analysis is accomplished through a series of deep learning networks that have been trained on vast amounts of data, with real-world variability, from the 100 plus diagnostic pathology labs Visiopharm is working with today.
The decision to work with Visiopharm is the result of their experience and documentation of the processes for future validated use of AI-driven image analysis.
Some of the solutions purchased include a full IHC panel of breast cancer algorithms as well as a H&E lymph node metastasis identification algorithm. These packaged analysis algorithms, or APPs, are already IVDR cleared in Europe, where they are used in a clinical setting. In the United States, these APPs are for research use only (RUO) and not for diagnostic purposes.
Michael Grunkin, Visiopharm CEO, said:
“We are very excited about this collaboration. There are very few organizations in this world with more practical experience and profound insights in digital pathology and anatomic pathology workflows than Dr. Anil Parwani and his team at the OSUCCC – James. Combined with our expertise and experience in launching AI-driven precision pathology in multiple diagnostic pathology labs in Europe, we have an opportunity to create multiplicative value in how we both think about and launch integrated computational assays for precision pathology.”
Amanda Lowe, Managing Director, Americas, Visiopharm, said:
“This is a powerful example of research being applied to translate the value of AI-powered digital pathology. We have listened carefully to the recommendations from Dr. Parwani and his team, and through that process, we have come to understand the multiple parameters diagnostic AI-solutions need, to deliver meaningful results. Also, the importance of maintaining a vendor agnostic approach with scanners, LIMS/PACS systems, and staining platforms. Visiopharm is leveraging 20 years’ experience serving the team at OSUCCC – James. I have no doubt we will learn even more in this next phase of our work together.”
Dr Anil Parwani, Vice Chair of Anatomic Pathology, and member of the Visiopharm Scientific Advisory Board, said:
“It is with great excitement that we begin to explore use of these powerful tools in a clinical context and environment. Digital diagnostic workflows are necessary for artificial intelligence to make a meaningful impact in digital pathology labs, where efficiency and precision are imperative. We are confident that the outcomes will benefit tissue pathology as a professional discipline, and ultimately the care of patients.”
Visiopharm® is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs provide decision support. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 750 customer accounts and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, The Netherlands and United States.